CR10801A - Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine - Google Patents

Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine

Info

Publication number
CR10801A
CR10801A CR10801A CR10801A CR10801A CR 10801 A CR10801 A CR 10801A CR 10801 A CR10801 A CR 10801A CR 10801 A CR10801 A CR 10801A CR 10801 A CR10801 A CR 10801A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical composition
modified release
nsaid
coated microspheres
muscle relaxant
Prior art date
Application number
CR10801A
Other languages
English (en)
Inventor
Salgado Lopez Enrique Raul Garcia
Hernandez Gustavo Barranco
Paniagua Angelica Arzola
Lopez Luis Fernando Poot
Rodriguez Francisco Escorcia
Original Assignee
Lab Senosiain S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Senosiain S A De C V filed Critical Lab Senosiain S A De C V
Publication of CR10801A publication Critical patent/CR10801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica de liberacion modificada en capsulas con microesferas recubiertas que comprende la combinacion de dos principios activos de tiempos de concentracion plasmatica radicalmente diferentes, estos son un musculo relajante (tizanidina) y un analgesico antiinflamatorio no esteroide (meloxicam), vehiculos o excipientes farmaceuticamente aceptables.
CR10801A 2006-10-18 2009-05-18 Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine CR10801A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06012024 2006-10-18

Publications (1)

Publication Number Publication Date
CR10801A true CR10801A (es) 2009-07-03

Family

ID=39313650

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10801A CR10801A (es) 2006-10-18 2009-05-18 Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine

Country Status (16)

Country Link
US (1) US20100166856A1 (es)
EP (1) EP2085076B1 (es)
AR (1) AR073435A1 (es)
AT (1) ATE499089T1 (es)
BR (1) BRPI0718368A2 (es)
CA (1) CA2670690C (es)
CL (1) CL2007002975A1 (es)
CO (1) CO6140021A2 (es)
CR (1) CR10801A (es)
DE (1) DE602007012751D1 (es)
EC (1) ECSP099348A (es)
ES (1) ES2361883T3 (es)
GT (1) GT200900089A (es)
PE (1) PE20081464A1 (es)
UY (1) UY30636A1 (es)
WO (1) WO2008047208A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2381937A2 (en) 2008-12-31 2011-11-02 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
AU2009352681B2 (en) * 2009-09-17 2014-11-20 Upsher-Smith Laboratories, Llc A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
PL2338473T3 (pl) 2009-12-18 2017-07-31 Mdm S.P.A. Postacie farmaceutycznej dawki tizanidyny i drogi jej podawania
BRPI1103205A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab Ltda Composição farmacêutica oral e uso da composição farmacêutica oral
WO2013159151A1 (en) * 2012-04-27 2013-10-31 Troy Laboratories Pty Ltd Combination meloxicam and xylazine therapy in animals
EP2977045A1 (en) * 2014-07-21 2016-01-27 Sanovel Ilac Sanayi ve Ticaret A.S. Zaltoprofen and muscle relaxant combinations
US10813916B2 (en) * 2015-05-29 2020-10-27 Jubilant Generics Limited Immediate release pharmaceutical composition of tizanidine
US20190060287A1 (en) * 2017-08-28 2019-02-28 Adare Pharmaceuticals, Inc. Tizanidine formulations
CA3217139A1 (en) * 2021-04-27 2022-11-03 Sang-Jin Lee Composition for preventing or treating muscular disease, comprising oxicam-based compound
CN113398096A (zh) * 2021-06-27 2021-09-17 烟台大学 一种含有美洛昔康的长效注射微球及其制备方法
CN120827566A (zh) * 2024-04-19 2025-10-24 四川科瑞德制药股份有限公司 替扎尼定美洛昔康复合物及其制备方法和其用途
WO2025217938A1 (en) * 2024-04-19 2025-10-23 Sichuan Credit Pharmaceutical Co., Ltd Tizanidine-meloxicam complex and preparation method and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
JP5502254B2 (ja) * 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
US8502335B2 (en) 2009-07-29 2013-08-06 Taiwan Semiconductor Manufacturing Company, Ltd. CMOS image sensor big via bonding pad application for AlCu Process

Also Published As

Publication number Publication date
EP2085076A4 (en) 2010-03-17
US20100166856A1 (en) 2010-07-01
DE602007012751D1 (de) 2011-04-07
CA2670690A1 (en) 2008-04-24
EP2085076B1 (en) 2011-02-23
ECSP099348A (es) 2009-06-30
CO6140021A2 (es) 2010-03-19
AR073435A1 (es) 2010-11-10
UY30636A1 (es) 2008-05-02
GT200900089A (es) 2012-01-13
CL2007002975A1 (es) 2008-01-04
WO2008047208A1 (es) 2008-04-24
ES2361883T3 (es) 2011-06-24
CA2670690C (en) 2014-12-30
BRPI0718368A2 (pt) 2013-11-12
EP2085076A1 (en) 2009-08-05
ATE499089T1 (de) 2011-03-15
PE20081464A1 (es) 2008-12-31

Similar Documents

Publication Publication Date Title
UY30636A1 (es) Composision farmaceutica de liberacon modificada de un musculo relajante y un aine
UY31647A1 (es) Forma de dosificación farmacéutica para la administración oral de inhibidor de tirosina quinasa
CL2012000626A1 (es) Composición farmacéutica oral de liberación sostenida, que comprende dentro de una forma de dosificación única, (i) una matriz hidrofílica, (ii) una cantidad terapéuticamente eficaz de un compuesto no opioide que contiene amina, (iii) una sal de un fármaco aine, y (iv) opcionalmente un surfactante aniónico.
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
MX2009010289A (es) Composiciones para administracion nasal.
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
CL2008001966A1 (es) Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques.
IL194885A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
WO2008146178A3 (en) A novel tablet dosage form
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
CR20110267A (es) Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
CL2015000375A1 (es) Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras.
NO20085414L (no) Farmasoytiske preparater for vedvarende frigivelse av fenylefrin
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
DK1711169T3 (da) Coatede mikrodepottabletter med venlafaxinhydrochlorid
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
CO6351711A2 (es) Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina